Anterior uveitis is a recognised ocular complication of sarcoidosis that demands prompt, targeted management. This page outlines the clinical scenario and signals when escalation beyond local ocular therapy is warranted.
In patients with sarcoidosis who develop anterior uveitis, the initial approach relies on local therapy — corticosteroid eye drops to suppress intraocular inflammation and cycloplegic drops to relieve pain and prevent intraocular scarring.
When anterior uveitis in the context of sarcoidosis is inadequately controlled by local measures, or when the disease course warrants systemic intervention, a structured escalation approach is required.
The protocol for sarcoidosis with anterior uveitis that requires systemic management involves consideration of cytotoxic agents — a drug class with documented efficacy in sarcoid-related uveitis. For cases that prove refractory, biologic therapy targeting specific inflammatory pathways may be incorporated.
The full selection, sequencing, and criteria for each option are detailed in the complete protocol.
Anterior uveitis usually can be managed with local therapy using corticosteroid eye drops to suppress inflammation and cycloplegic eye drops to suppress pain and avoid intraocular scarring.
Cytotoxic drugs such as methotrexate, azathioprine, and mycophenolate mofetil have been used with success.
For severe cases, infliximab has been useful.
In uveitis in general – including uveitis related to sarcoidosis – either infliximab or adalimumab has been useful in refractory cases.
View source ↗